Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein  by Krug, Robert M. et al.
Minireview
Intracellular warfare between human influenza viruses and human cells:
the roles of the viral NS1 protein
Robert M. Krug,* Weiming Yuan, Diana L. Noah, and Anita Ghate Latham
Institute for Cellular and Molecular Biology, Section of Molecular Genetics and Microbiology, University of Texas at Austin, Austin, TX 78712, USA
Received 6 December 2002; returned to author for revision ; accepted 7 January 2003
Introduction
Virus-infected mammalian cells are a battleground: cells
mount antiviral defenses against the virus, and these de-
fenses are countered by the infecting virus. The eventual
outcome of this war is a major determinant of the patho-
genesis of the virus infection.
In this minireview we will discuss the intracellular war-
fare between human influenza viruses and human cells.
Influenza A and B viruses, two of the four influenza virus
genera, cause widespread epidemics in humans (Lamb and
Krug, 2001; Wright and Webster, 2001). Influenza A vi-
ruses, which have been isolated from a wide variety of avian
and mammalian species, are responsible for the human
pandemics that have caused high mortality rates, and the
highly pathogenic virus that was transmitted from chickens
to humans in Hong Kong in 1997 is an influenza A virus
(Wright and Webster, 2001). Influenza B virus appears to
infect only humans (Wright and Webster, 2001), although
influenza B virus has recently been isolated from seals
(Osterhaus et al., 2000). Both influenza A and B viruses
contain eight genomic RNA segments, and most of the
proteins encoded by the corresponding genomic RNA seg-
ments serve similar functions (Lamb and Krug, 2001).
We will focus solely on the role of one virus-encoded
protein in the virus–cell war: the NS1 protein, which is
encoded by the smallest genomic RNA segment of both
influenza A and B viruses. This protein is designated as
nonstructural (NS) because it is synthesized in infected
cells, but is not incorporated into virions (Lamb and Krug,
2001). The NS1 proteins of influenza A virus (NS1A pro-
tein) and influenza B virus (NS1B protein) share one func-
tion: the binding of double-stranded RNA (dsRNA) via their
N-terminal RNA-binding domains (Hatada and Fukuda,
1992; Lu et al., 1995; Wang et al., 1999; Yuan et al., 2002)
(Fig. 1). The three-dimensional structure of the RNA-bind-
ing domain of the NS1A protein exhibits a novel dimeric
six-helical chain fold (Chien et al., 1997; Liu et al., 1997)
that differs from that of any other known RNA-binding
proteins in the structural database, including the dsRNA-
binding domain (dsRBD) found in many cellular proteins
(Ryter and Schultz, 1998; Ramos et al., 2000). Computer
modeling and mutagenesis experiments indicate that the
RNA-binding domain of the NS1B protein exhibits a
dimeric six-helical chain fold similar to that of the NS1A
RNA-binding domain except that there are large loops be-
tween the three -helices in each monomer (Wang et al.,
1999; Yuan et al., 2002). The RNA-binding domains of the
NS1A and NS1B bind dsRNA with low affinity, approxi-
mately 5000-fold lower than the dsRBDs found in cellular
proteins (McCormack and Samuel, 1995; Schmedt et al.,
1995; Wang et al., 1999; Ohman et al., 2000; Tian and
Mathews, 2001; Yuan et al., 2002). All other functions of
the NS1A and NS1B proteins differ markedly, as will be
discussed later, resulting in major differences in the mech-
anisms by which these two proteins mediate viral counter-
measures against cellular antiviral responses.
The first battle: the initial interferon-/ (IFN-/)-
independent cellular antiviral response
Crucial cellular defenses against infection by mamma-
lian viruses take place in initially infected cells prior to the
synthesis of IFN-/ (Zhu et al., 1997; Maniatis et al.,
1998; Navarro et al., 1998; Wathelet et al., 1998; Weaver et
al., 1998; Yoneyama et al., 1998; Preston et al., 2001;
Simmen et al., 2001; Kim et al., 2002). A major cellular
response is the activation of transcription factors that con-
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trol the expression of antiviral genes. The initial activation
of such transciption factors in response to virus infection is
not mediated by IFN-/ and does not require viral protein
synthesis (Daly and Reich, 1993, 1995; Zhu et al., 1997;
Navarro et al., 1998; Wathelet et al., 1998; Yoneyama et al.,
1998; Boyle et al., 1999; Guo et al., 2000; Chin and Cress-
well, 2001; Iwamura et al., 2001; Preston et al., 2001;
Simmen et al., 2001; Kim et al., 2002; Noah et al., 2003).
Two transcription factors, interferon regulatory factor-3
(IRF-3) and IRF-7, are activated and combine with the
transcriptional coactivators p300 and CREB-binding protein
to form a transcription complex (Navarro et al., 1998;
Wathelet et al., 1998; Weaver et al., 1998; Yoneyama et al.,
1998; Preston et al., 2001; Kim et al., 2002). This complex
(virus-activated factor or VAF) binds to a subset of the
IFN-/-stimulated response elements (ISREs) in the pro-
moters of cellular genes, thereby inducing their transcrip-
tion. Because some of the proteins encoded by these genes
have antiviral activities (Boyle et al., 1999; Chin and Cress-
well, 2001; Simmen et al., 2001; Kim et al., 2002), this
IFN-/-independent virus-induced activation of cellular
transcription constitutes an early antiviral response of cells.
Viruses need to mount countermeasures against such an
early antiviral response to allow the virus to replicate (Chin
and Cresswell, 2001). This is the initial battle in the intra-
cellular warfare between mammalian cells and many mam-
malian viruses.
Influenza A virus
As is the case with other mammalian viruses, infection of
human cells with influenza A virus induces the IFN-/-
independent activation of IRF-3 and transcription of ISRE-
controlled cellular genes (Kim et al., 2002). Several differ-
ent assays established that IRF-3 is activated (Kim et al.,
2002; Ehrhardt, C. and Ludwig, S., personal communica-
tion). Cycloheximide does not inhibit IRF-3 activation (Kim
et al., 2002), indicating that the synthesis of virus-encoded
proteins is not required for this activation. In addition,
IRF-3 activation occurs after infection of GRE cells (Kim et
al., 2002), which do not produce IFN-/ (Bandyopadhyay
et al., 1995), indicating that activation is independent of
IFN-/. A nuclear runoff transcription assay demonstrated
that the transcription of the ISRE-controlled p56 gene is
induced, thereby establishing that the IRF-3 which is acti-
vated after influenza A virus infection functions in tran-
scription (Kim et al., 2002). In contrast to other viruses, this
early IFN-/-independent activation of the synthesis of
cellular antiviral pre-mRNAs after influenza A virus infec-
tion does not result in the production of mature antiviral
mRNAs, indicating that the posttranscriptional processing
of these cellular antiviral pre-mRNAs is inhibited (Kim et
al., 2002). As a result, this early antiviral response of cells
is effectively countered because the antiviral proteins en-
coded by these cellular genes are not synthesized. Conse-
quently, influenza A virus wins the initial battle in the
intracellular war with human cells.
A substantial body of evidence indicated that inhibition
of the posttranscriptional processing of these cellular anti-
viral pre-mRNAs is most likely mediated by the viral NS1A
protein. Transfection experiments and in vitro assays estab-
lished that the NS1A protein inhibits the posttranscriptional
processing of cellular pre-mRNAs by binding and inhibiting
the function of two cellular proteins that are required for the
3-end processing of cellular pre-mRNAs: the 30-kDa sub-
unit of the cleavage and polyadenylation specificity factor
(CPSF) and poly(A)-binding protein II (PABII) (Nemeroff
et al., 1998; Chen et al., 1999; Chen and Krug, 2000; Li et
al., 2001). This inhibition of the cellular 3-end processing
machinery does not affect the addition of poly(A) tails onto
viral mRNAs because the poly(A) tails of viral mRNAs are
produced by the viral polymerase, and not by the cellular
3-end processing machinery (Robertson et al., 1981; Poon
et al., 1999). The binding site in the NS1A protein for the
cellular 30-kDa CPSF subunit is centered around amino
acid 186 and the PABII-binding site is located in the 223–
237 amino acid region (Li et al., 2001) (Fig. 1A). Mutation
of the NS1A-binding site for the 30-kDa CPSF subunit
eliminates the ability of NS1A to inhibit 3-end cleavage of
pre-mRNAs in transient transfection assays, establishing
that this NS1A-binding site is required for the inhibition of
3-end processing of cellular pre-mRNAs (Li et al., 2001).
RNA binding by the NS1A protein plays no role in this
inhibition. Several lines of evidence established that these
transfection experiments and in vitro assays mirror events in
infected cells: (i) the inhibition of 3-end processing of
Fig. 1. The binding sites of cellular proteins on the domains of the NS1A and NS1B proteins. Amino acid residue numbers are denoted.
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newly synthesized cellular pre-mRNAs occurs in influenza
A virus-infected cells (Chen et al., 1999; Shimuzu et al.,
1999); (ii) this inhibition is mediated by the NS1A protein,
as shown by using NS1A virus mutants (Chen et al., 1999;
Shimuzu et al., 1999); (iii) cellular pre-mRNAs with un-
processed or incompletely processed 3 ends accumulates in
cells infected by these mutant viruses (Chen et al., 1999;
Shimuzu et al., 1999); and (iv) the NS1A protein is physi-
cally associated with 30-kDa CPSF in influenza A virus-
infected cells (Nemeroff et al., 1998). As a result of the
inhibition of 3-end processing, cellular mRNAs are not
exported from the nucleus at early times after virus infection
(Katze and Krug, 1984; Chen et al., 1999).
To obtain definitive proof that the 30-kDa CPSF–NS1A
protein interaction plays a crucial role in the viral posttran-
scriptional countermeasure against the early, IFN-/-inde-
pendent cellular antiviral response, a recombinant influenza
A/Udorn/72 virus was generated that encodes an NS1A
protein which has an altered amino acid sequence centered
around amino acid 186 and as a result does not bind the
30-kDa subunit of CPSF (Noah et al., 2003). This recom-
binant virus (CPSF mutant virus) is substantially attenuated,
indicating that this binding site in the NS1A protein is
required for efficient virus replication. The effect of this
NS1A mutation on the IFN-/-independent antiviral re-
sponse was analyzed by infecting GRE cells with the CPSF
mutant virus: cellular antiviral mRNAs are produced and
translated as a result of the early IFN-/-independent ac-
tivation of the transcription of cellular antiviral genes (Noah
et al., 2003). Consequently, this mutation in the NS1A
protein relieves the inhibition of the posttranscriptional pro-
cessing of these cellular antiviral pre-mRNAs that occurs in
cells infected by wild-type virus, establishing that this viral
countermeasure is largely mediated by the binding of the
30-kDa CPSF subunit to the NS1A protein. Thus, one of the
major roles of the NS1A protein-mediated inhibition of the
processing of newly synthesized cellular pre-mRNAs is the
inhibition of the early, IFN-/-independent production of
cellular antiviral mRNAs. The mechanism by which the
NS1A protein interaction with 30-kDa CPSF enables influ-
enza A virus to win the initial battle in the intracellular war
between human cells and human influenza A virus is dia-
grammed in Fig. 2A.
Influenza B virus
Infection of human cells with influenza B virus also
induces the IFN-/-independent activation of IRF-3 and
transcription of ISRE-controlled cellular genes (Kim et al.,
2002). This transcription results in the production of anti-
viral cellular mRNAs and antiviral proteins, in contrast to
the situation in cells infected with influenza A virus (Kim et
al., 2002). It is not surprising that the efficient production of
functional cellular antiviral mRNAs occurs in influenza B
virus-infected cells (Kim et al., 2002), because the NS1B
protein does not bind either 30-kDa CPSF or PABII (Fig.
1B) and does not inhibit the posttranscriptional processing
of cellular pre-mRNAs (Wang and Krug, 1996).
Influenza B virus activates IRF-3 even when transcrip-
tion by the virion-associated polymerase is blocked by prior
Fig. 2. The initial battle in the intracellular war between human cells and human influenza A and B viruses. Both of these viruses induce the
IFN-/-independent activation of IRF-3 and transcription of ISRE-controlled cellular genes, some of which encode antiviral proteins. (A) Influenza A virus.
To counter this cellular antiviral response, the influenza A viral NS1A protein inhibits the posttranscriptional processing of these cellular antiviral
pre-mRNAs. This inhibition is largely mediated by the binding of the NS1A protein to the 30-kDa subunit of CPSF. Consequently, influenza A virus wins
this initial battle. (B) Influenza B virus. The transcription of ISRE-controlled cellular genes results in the production of antiviral cellular mRNAs and antiviral
proteins. The influenza B viral NS1B protein binds one of these proteins, the ubiquitin-like ISG15 protein, and inhibits its conjugation to its target proteins.
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ultraviolet light (UV) irradiation of the virus (Kim et al.,
2002). Thus, influenza B virus may be similar to two DNA
viruses, cytomegalovirus and herpes simplex virus, which
activate the transcription of ISRE-controlled genes via an
initial interaction of the virus with the cell surface, either the
binding of virions to receptors on the cell surface or the
subsequent entry of virions into the cell (Boyle et al., 1999;
Chin and Cresswell, 2001; Preston et al., 2001; Simmen et
al., 2001). In contrast, UV-irradiation of influenza A virus
abrogates its ability to activate IRF-3 (Kim et al., 2002),
suggesting that transcription by the virion-associated poly-
merase is needed. Such viral transcription may generate
virus-encoded, double-stranded RNA molecules, which
have been postulated to be responsible for the activation of
IRF-3 in cells infected by other negative-strand RNA vi-
ruses (Daly and Reich, 1993, 1995; Wathelet et al., 1998;
Weaver et al., 1998; Yoneyama et al., 1998; Guo et al.,
2000; Iwamura et al., 2001).
Because these early antiviral proteins are synthesized,
subsequent countermeasures by influenza B virus would
likely be needed. It is possible that one of the influenza B
virus countermeasures is mediated by the unique ability of
the NS1B protein to bind one of the predominant early
antiviral proteins, the ISG15 protein (Yuan et al., 2002),
which is an ubiquitin-like protein (Loeb and Hass, 1992,
1994). This binding results in the inhibition of conjugation
of ISG15 to its target proteins in both in vitro and influenza
B virus-infected cells (Yuan and Krug, 2001). The NS1B
protein inhibits the first step in conjugation, which is cata-
lyzed by an enzyme that was identified as UBE1L (Yuan
and Krug, 2001). UBE1L was originally identified because
its gene is deleted in many lung cancer cells (Carritt et al.,
1992; Kok et al., 1993, 1995). The cellular and viral events
that occur during the initial battle in the intracellular war
between human cells and human influenza B virus are
diagrammed in Fig. 2B. It has not yet been possible to
determine how ISG15 conjugation affects the replication of
influenza B virus, in large part because ISG15 conjugation
occurs very slowly in all tissue culture cell lines that have
been tested. Free ISG15 is produced for an extended period
of time (for approximately 12–16 hs) before conjugation of
ISG15 to its target proteins begins (Loeb and Haas, 1992;
Yuan and Krug, 2001). Because of this delay, significant
ISG15 conjugation does not occur until after most influenza
B virus-specific events have already taken place. The delay
in ISG15 conjugation may indicate that the ISG15 conju-
gation pathway is defective in these cell lines, and/or that
the principal ISG15 deconjugating enzyme USP43 (Liu et
al., 1999; Malakhov et al., 2002) is produced in excess in
these cell lines. To elucidate the role of the NS1B protein-
mediated inhibition of ISG15 conjugation, it will be neces-
sary to identify the protein targets of ISG15 conjugation and
to determine how ISG15 conjugation affects the activities of
these target proteins.
Part of the ISG15 protein-binding site is located in one of
the loops in the N-terminal binding domain of the NS1B
protein (Yuan et al., 2002). Because there are two copies of
this loop, it is likely that two ISG15 protein molecules bind
to each dimeric NS1B protein. The other part of the ISG15-
binding site is in the 94–103 amino acid region of the NS1B
protein (Fig. 1B). The function of the rest of the effector
domain has not yet been determined. The presence of this
particular loop in the NS1B RNA-binding domain enables
the NS1B protein to carry out a biological function—the
inhibition of ISG15 conjugation—that is not carried out by
the NS1A protein whose RNA-binding domain lacks this
loop (Yuan et al., 2002). Thus, the N-terminal region of the
NS1B protein binds not only dsRNA but also a specific
cellular protein, and thus, differs from the corresponding
region of the NS1A protein, which appears to function
solely as a dsRNA-binding domain. Thus, the divergence of
the NS1A and NS1B proteins results in differences in the
functions of not only their effector domains but also their
N-terminal domains.
Activation of PKR: a second virus-cell battle prior to
the production of IFN-/
Another cellular antiviral response prior to the produc-
tion of IFN-/ is mediated by protein kinase R (PKR),
which can be activated by dsRNA or by interaction with
specific proteins (Patel and Sen, 1998; Ito et al., 1999; Patel
et al., 2000; D’Acquisto and Ghosh, 2001; Peters et al.,
2001; Williams, 2001). Substantial amounts of PKR and its
mRNA are expressed constitutively in the absence of IFN-
/ (Der et al., 1998; Williams, 2001). Activated PKR
phosphorylates the -subunit of the translation initiation
factor eIF2, resulting in the inhibition of protein synthesis
and hence virus replication (reviewed in Safer, 1983).
Influenza viruses
In cells infected by influenza A virus, the NS1A protein
plays a major role in inhibiting the activation of PKR
(Hatada et al., 1999; Bergmann et al., 2000). It is not known
whether the inhibition of constitutively expressed PKR by
the NS1A protein is mediated by its RNA-binding domain.
The RNA-binding domain is sufficient for the inhibition of
PKR activation in vitro, but this inhibition requires a high
concentration of the NS1A protein (Lu et al., 1995), pre-
sumably due to the low affinity of the NS1A RNA-binding
domain for dsRNA. This in vitro result does not establish
that the low-affinity NS1A RNA-binding domain accesses
dsRNA in vivo, where this domain has to compete with
many cellular proteins that have higher affinities for
dsRNA. In fact, the amino acids of the NS1A protein that
have been implicated in the inhibition of PKR do not in-
clude those that bind directly to the dsRNA target (R38,
K41) nor those that are required for the dimerization of the
RNA-binding domain, but instead include an amino acid in
the effector domain (Hatada et al., 1999). Consistent with
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these results, it has been reported that the NS1A protein
interacts directly with PKR to block its activation (Tan and
Katze, 1998). Nonetheless, it has not been ruled out that
binding of dsRNA by the NS1A RNA-binding domain par-
ticipates in the inhibition of PKR activation. More studies
are needed to establish the mechanism by which the NS1A
protein inhibits PKR activation in infected cells. It has not
been determined whether the NS1B protein of influenza B
virus plays a role in the inhibition of PKR activation.
The production of IFN-/: a third virus-cell battle
Infection of mammalian cells with many viruses also
activates the transcription factors that induce the transcrip-
tion of the IFN- and IFN- genes (Biron and Sen, 2001).
The complex of transcription factors required for the induc-
tion of IFN- transcription, which has been termed the
enhanceosome, contains two of the factors present in the
VAF, IRF-3 and IRF-7, NF-B plus additional factors (Ma-
niatis et al., 1998; Wathelet et al., 1998). The IFN-/
protein molecules synthesized in initially infected cells are
secreted and bind to cell-surface receptors to establish an
antiviral state via the activation of transcription factors
(Biron and Sen, 2001). Activation results in the formation of
a protein complex, called ISGF-3 (Darnell et al., 1994),
which differs from VAF. The ISGF-3 complex binds to all
the ISREs of cellular genes, thereby inducing their tran-
scription. Thus, some ISREs can bind both VAF and
ISGF-3, whereas other ISREs can bind only the ISGF-3 that
is activated by IFN-/ (Wathelet et al., 1992, 1998). Se-
creted IFN-/ may not provide much protection to initially
infected cells that produce IFN-/ because these cells
already have an established virus infection. Rather, it is
likely that the primary role of IFN-/ is to protect neigh-
boring uninfected cells, thereby inhibiting virus spread. Vi-
ruses need to mount countermeasures to inhibit the produc-
tion of IFN-/ by the cell. This is another key battle in the
intracellular warfare between mammalian cells and mam-
malian viruses.
Influenza A virus
Many investigators have shown that IRF-3 and NF-B
are activated, and that IFN-/ is produced in cells infected
by influenza A virus (Issacs and Lindemann, 1957; Pahl and
Baeuerle, 1995; Ronni et al., 1997; Flory et al., 2000;
Matikainen et al., 2000; Hiscott et al., 2001; Huang et al.,
2001; Julkunen et al., 2001; Geiss et al., 2002; Kim et al.,
2002; Noah et al., 2003). Microarray analysis of the cellular
mRNAs produced after influenza A virus infection of hu-
man monocyte-derived dendritic cells established that IFN-
1, and several IFN- species, are produced (Huang et al.,
2001). Dendritic cells produce more IFN-/ than human
lung epithelial cells during influenza A virus infection
(Julkunen et al., 2001). Nonetheless, the synthesis of IFN-
mRNA in influenza A virus-infected human lung epithelial
cells is readily detected by an RNase protection assay (Noah
et al., 2003), and microarray analysis, which is considerably
less sensitive than the RNase protection assay, showed that
a substantial number of IFN-induced mRNAs, specifically
including MxA mRNA, are produced (Geiss et al., 2002).
As IFN- transcription requires activated IRF-3 and NF-B
(Maniatis et al., 1998; Wathelet et al., 1998), these results
provide further evidence that these two transcription factors
are activated during influenza A infection, in conflict with
two studies (Talon et al., 2000; Wang et al., 2000).
These results show that even in the presence of a func-
tional 30-kDa CPSF-binding site in the wild-type NS1A
protein, some IFN- pre-mRNA escapes the inhibition of
posttranscriptional processing mediated by this binding site.
Some posttranscriptional processing of several other virus-
induced cellular pre-mRNAs also occurs in wild-type influ-
enza A virus-infected cells, as detected by microarray anal-
ysis, e.g., the production of cellular mRNAs involved in the
STAT and apoptotic pathways (Geiss et al., 2001, 2002;
Huang et al., 2001). These observations suggest that the
function of the NS1A-binding site for 30-kDa CPSF is
regulated during wild-type virus infection. One possibility
is that the inhibition of posttranscriptional processing of
cellular pre-mRNAs is relieved as a result of the activation
of the nuclear export signal (NES) of the NS1A protein (Li
et al., 1998). This NES, which comprises amino acids 137–
146 of the NS1A protein (Fig. 1A), does not function in
transfected cells, but is activated during virus infection.
Activation of the NS1A NES might cause the nuclear export
of those NS1A protein molecules that were imported into
the nucleus at early times of infection, thereby eliminating
the inhibition caused by the NS1A binding to at least some
CPSF molecules. It is not clear why this would be advan-
tageous for the virus. Perhaps cytoplasmic accumulation of
the NS1A protein is needed to inhibit PKR activation.
Because mutation of the 30-kDa CPSF-binding site in
the NS1A protein eliminates the inhibition of posttranscrip-
tional processing of cellular pre-mRNAs throughout infec-
tion, it is not surprising that the production of IFN- mRNA
is enhanced in human lung epithelial cells infected by the
CPSF mutant virus. The enhanced production of IFN-
would be expected to induce an antiviral state in neighbor-
ing uninfected cells more rapidly and more efficiently,
thereby contributing to the attenuation of the CPSF mutant
virus. Because the NS1A protein encoded by the CPSF
mutant virus retains the binding site for the PABII protein,
the cellular mRNAs synthesized in cells infected by this
mutant virus should contain short poly(A) tails approxi-
mately 10 nucleotides in length. It is reasonable to expect
that cellular mRNAs containing full-length poly(A) tails
would be exported into the cytoplasm more efficiently,
would be more stable, and/or would be translated more
efficiently. Consequently, it would be predicted that an
influenza A virus encoding an NS1A protein which contains
mutated binding sites for both 30-kDa CPSF and PABII
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would be more attenuated than the CPSF mutant virus.
Conversely, we would predict that reduced production of
IFN- mRNA would increase the virulence of influenza A
virus. Reduction in IFN- mRNA production would be
expected if the NS1A protein-mediated inhibition of the
posttranscriptional processing of cellular pre-mRNAs were
maintained throughout infection. Thus, this key battle in the
intracellular war between influenza A virus and human cells
is a delicately regulated contest that most likely ends in a vic-
tory for the cell because the amount of IFN- mRNA that
escapes the NS1A protein-mediated inhibition of posttranscrip-
tional processing limits virus spread to a tolerable level.
Influenza B virus
Definitive studies have not been reported on the synthe-
sis of IFN-/ mRNA during infection by influenza B virus.
We have found that IFN- mRNA is synthesized in influ-
enza B virus-infected cells (Min, J.-Y. and Krug, R.M.,
unpublished experiments). This is not surprising consider-
ing that the NS1B protein of influenza B virus does not
inhibit the posttranscriptional processing of cellular mRNAs
(Wang and Krug, 1996).
The virus–cell battle after the production of IFN-/
The IFN-/ produced in initially infected cells protects
neighboring uninfected cells against virus infection. Treat-
ment of human cells with IFN-/ stimulates the transcrip-
tion of several hundred human genes (Der et al., 1998),
resulting in at least an equivalent number of IFN-induced
proteins, many of which participate in the antiviral response
(Der et al., 1998; Stark et al., 1998).
Influenza viruses
The replication of influenza A virus is inhibited in IFN-
/-treated human cells in a dose-dependent manner (Ronni
et al., 1997). At the highest level of IFN-/ used, replica-
tion is almost completely inhibited. One of the IFN-/-
induced gene products in human cells is the MxA protein,
which has been shown to be largely responsible for the
IFN-/-induced inhibition of influenza A virus replication
(Pavlovic et al., 1990, 1992; Ronni et al., 1997). We have
found that influenza B virus is also almost completely in-
hibited in IFN-/-treated human cells (Min, J.-Y. and
Krug, R.M., unpublished experiments). Consequently, the
NS1A and NS1B proteins do not protect influenza A and B
viruses, respectively, against the IFN-/-mediated antiviral
response of human cells, and influenza A viruses (with one
apparent exception described below) and influenza B viruses
lose this battle and the war between human cells and the virus.
However, one NS1A protein apparently behaves differ-
ently: the NS1A protein of the highly pathogenic virus that
was transmitted from chickens to humans in Hong Kong in
1997 protects the virus against the antiviral proteins pro-
duced in pig cells after IFN treatment (Seo et al., 2002).
Such protection requires the presence of glutamic acid at
position 92 in the effector domain of the NS1A protein (see
Fig. 1A). The mechanism of this protection has not been
established, and it is not known whether similar protection
occurs in human cells. Future studies on this protection
mechanism may be expected to elucidate additional func-
tions of the NS1A protein in the virus–cell intracellular war.
A different interpretation of the intracellular war
Despite all the evidence that the influenza virus NS1A
and NS1B proteins are multifunctional proteins, one group
of investigators has argued that these proteins have only a
single required function, namely the binding of dsRNA by
the NS1 RNA-binding domain (summarized in Garcia-Sas-
tre, 2001). These investigators generated mutant influenza A
viruses that express NS1A proteins containing large C-
terminal deletions. The most extensively studied mutant
virus encodes a NS1A protein that is 124–126 amino acids
long and consequently contains the RNA-binding domain
and 51–53 amino acids of the effector domain (see Fig. 1A).
Conflicting results have been reported concerning the
growth of this mutant virus in tissue culture cells containing
intact IFN-/ genes: highly attenuated growth in MDCK
(canine kidney) cells (Egorov et al., 1998); but little or no
attenuation in MDBK (bovine kidney) cells (Wang et al.,
2002). Attenuation of virus growth is consistent with the
microarray results obtained by this group of investigators
using human epithelial lung cells (Geiss et al., 2002). This
analysis showed that the amount of IFN-/-induced cel-
lular mRNAs produced during infection by this mutant virus
was substantially increased compared to that produced by
wild-type influenza A virus. The results with the CPSF
mutant virus (Noah et al., 2003) explain these microarray
data. Because the truncation of the NS1A protein removes
the binding site for the 30-kDa subunit of CPSF, posttran-
scriptional processing of IFN- pre-mRNA would not be
inhibited throughout infection, resulting in increased pro-
duction of IFN-induced mRNAs.
These investigators also inoculated inbred mice with the
mutant influenza A viruses that express NS1A proteins
containing large C-terminal deletions (Wang et al., 2002).
Mice are not naturally infected with influenza viruses, but
can be experimentally infected with mouse-adapted influ-
enza virus strains (Wright and Webster, 2001). In addition,
it is necessary to use inbred mice strains that lack a func-
tional Mx gene, because the IFN-/-induced Mx protein
mediates selective resistance to influenza virus and as a
result influenza virus replication is blocked (Staehli and
Haller, 1987). Whereas cells from Mx-positive mice de-
velop an efficient antiviral state against influenza virus after
IFN-/ treatment (104-fold reduction in virus yield),
cells from Mx-negative mice are only weakly resistant to
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influenza virus after IFN-/ treatment (10-fold reduction
in virus yield) (Staehli et al., 1984). Consequently, inbred
Mx-negative mice possess a defective innate immune sys-
tem against influenza virus. These investigators found that
mutant viruses encoding either a 126 amino acid long NS1A
protein or a 73 amino acid long NS1A protein was attenu-
ated in Mx-negative mice, and that the addition of short
heterologous dimerization domains to the carboxy end of
the truncated NS1A proteins partially relieved this attenua-
tion (Wang et al., 2002). They claim that these results
indicate that the primary function of the effector domain in
these inbred mice is to stabilize the NS1A protein by pro-
viding an additional dimerization domain.
It remains to be established that these results with Mx-
negative inbred mice portray the roles of the NS1A protein
in countering cellular antiviral responses during influenza A
virus infections of natural hosts, including humans. The
effector domain of the NS1A protein that has evolved for
these natural infections contains 157–164 amino acids,
which have already been shown to be grouped into several
specific functional sequences, namely, a NES and binding
sites for two cellular 3-end processing factors, 30-kDa
CPSF and PABII (Li et al., 1998, 2001; Nemeroff et al.,
1998; Chen et al., 1999; Chen and Krug, 2000). It is ex-
tremely unlikely that these effector domain functions would
have been preserved during virus evolution if the primary,
or sole, role of the effector domain was the provision of a
short dimerization region to stabilize the 73 amino acid
RNA-binding domain. Undoubtedly, one of the important
selective pressures during the evolution of these effector
domain functions for human infections has been provided
by the IFN-induced human MxA gene, whose mouse coun-
terpart is absent in the inbred mice experiments described
above. In addition, it has been established that these con-
served effector domain functions operate during influenza A
virus infection of human cells. For example, as already
discussed, the 30-kDa binding site of the NS1A protein
mediates the inhibition of the posttranscriptional processing
of cellular pre-mRNAs that plays key roles in the viral
countermeasures against human antiviral responses (Nem-
eroff et al., 1998; Chen et al., 1999; Shimuzu et al., 1999;
Noah et al., 2003). In contrast, the specific function of the
low-affinity RNA-binding domain of the NS1A protein dur-
ing virus infection remains elusive. This RNA-binding do-
main does not play a role in the inhibition of the posttran-
scriptional processing of cellular pre-mRNAs (Li et al.,
1998) and does not prevent the activation of either IRF-3 or
NF-B by sequestering dsRNA (Pahl and Baeuerle, 1995;
Ronni et al., 1997; Flory et al., 2000; Hiscott et al., 2001;
Kim et al., 2002; Noah et al., 2003). Finally, it is not known
whether the inhibition of PKR activation by the NS1A
protein (Hatada et al., 1999; Bergmann et al., 2000) is
mediated by its RNA-binding domain. Nonetheless, it is
likely that the evolutionary conserved RNA-binding domain
does carry out at least one essential function during virus
infection, which remains to be identified.
Concluding remarks
Considerable progress has been made in understanding
the multiple activities of the influenza virus NS1A and
NS1B proteins and how these activities function in coun-
tering cellular antiviral responses. It has already been es-
tablished that the functions of the NS1A protein of influenza
A virus differ markedly from those of the NS1B protein of
influenza B virus, resulting in major differences in the
mechanisms by which these two proteins mediate viral
countermeasures against cellular antiviral responses. In fact,
this may be the greatest difference in function between
influenza A and B virus proteins. These differences in the
functions of the NS1A and NS1B proteins may be the basis
for many of the differences in the biological properties, host
range, and pathogenicity of these two influenza viruses.
Many intriguing questions remain about the roles of the
NS1A and NS1B proteins in the intracellular was between
human influenza viruses and human cells.
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